NAD Plus Community Reports
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ss-31* · *peptides/mots-c* · *circadian-sleep*
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
NAD Plus Community Reports doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for NAD Plus Community Reports yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ss-31* · *peptides/mots-c* · *circadian-sleep*
Who reports the strongest results
Three populations stand out:
-
IV NAD+ recipients — the delivery route produces the most acute and pronounced effects; within-infusion clarity and energy experiences are documented as distinctly powerful
-
Peri-menopausal and menopausal women — consistently report sustained energy, cognitive clarity, and emotional resilience improvements; community hypothesis is that the hormonal transition increases mitochondrial NAD+ demand
-
Long COVID and post-viral fatigue — NAD+ precursors (NR) are being studied in this population; community reports meaningful recovery acceleration
What the community actually says
The delivery route is the most important variable
Community is clear: the same molecule delivered differently produces substantially different experiences.
IV (250–1,000 mg per infusion): Most pronounced and acute. Within hours: energy, cognitive clarity, “fog lifting.” The full systemic availability is the reason.
SubQ (20–100 mg, 2–3× per week): Meaningful sustained effect; practical for ongoing home use. Less acute than IV but more consistent.
Oral NR/NMN: Lower bioavailability; subtler effects requiring 2–4 weeks of consistent use. The accessible entry point; maintained by many users as ongoing baseline between IV protocols.
Community layering strategy: IV quarterly for “reset” protocols; SubQ weekly for maintenance; oral daily as the foundation.
The two practical challenges — and their solutions
IV: chest tightness (rate-dependent)
The chest tightness during IV NAD+ infusions is the #1 first-timer concern — described as uncomfortable pressure, sometimes alarming. It is entirely rate-dependent. When the drip slows, it resolves within minutes. This is not cardiac — it reflects the rate of cellular NAD+ metabolism. Reputable IV clinics now brief patients on this before infusions. If you experience it: ask the nurse to slow the drip.
SubQ: injection site burn (temperature-dependent)
NAD+ solutions are typically acidic, and cold acidic solution burns on injection. Community fix: let the vial reach room temperature before injecting. This single change dramatically reduces the burn intensity. Most users describe the burn as manageable to mild once this is standard practice.
Who notices it most — the peri-menopausal women signal
Among all demographic groups, peri-menopausal and menopausal women report some of the most consistent and meaningful NAD+ responses in the community. Energy improvements described as “the best I’ve felt in years.” Cognitive clarity and emotional resilience both cited. Community hypothesis: the hormonal transition creates high mitochondrial NAD+ demand, making supplementation more impactful in this window than in younger adults or men.
Protocol as used by community
IV protocol: Initial series of 3–5 infusions over 1–2 weeks; quarterly maintenance infusions. Clinic-based.
SubQ protocol: 25–50 mg SubQ, 3× per week; vial at room temperature. Home self-administration.
Community layering: IV quarterly as reset + SubQ weekly + oral NR/NMN daily as foundation.
Cross-references
*peptides/ss-31*— complementary mitochondrial protection*peptides/mots-c*— complementary mitochondrial signaling; “mito stack” with SS-31*circadian-sleep*— NAD+ rhythm has circadian dependency; timing may matter
Commercial note
NAD+ is available through Alyve — use code OHM-15 at checkout for 15% off.